Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2005

View Archived Issues

New data on the pharmacokinetics and metabolism of viramidine

Atorvastatin prevents autoimmune disease by interfering with Ras and Rho GTPase prenylation

EGCG exerts neuroprotective and antiinflammatory actions in murine EAE

Monoclonal antibodies prevent hepatitis C viral reinfection

GB Therapeutics changes name to Cita NeuroPharmaceuticals

Therapeutic potential of the histamine H3 receptor antagonist ABT-239

Leinamycin prodrug activated by oxidative stress in prostate tumor cells

Xsira inlicenses adenosine for reduction of postoperative pain

Target selection in Celera Genomics and Abbott collaboration

NDA resubmission for indiplon capsules

FDA ready to review OrCel PMA application

Positive findings in proof-of-principle study for COL-3 in rosacea

Genentech extends support of Curis collaborative efforts

U.K. clearance for phase IIb CoFactor study in metastatic colorectal cancer

2ME2 receives orphan drug designation for ovarian cancer

Phase I study begins dosing for intranasal RSV vaccine

Lundbeck looks back at 2004

First small-molecule agonists of orphan estrogen-related receptors synthesized

PharmaFrontiers updates recent progress

Second year of SBIR funding supports GelVac evaluation

FDA approval of Liberte stent

New treatments for diabetes claimed by Arena

Antiobesity drugs disclosed in patents from Banyu and BMS

Bionaut and AnalytiCon Discovery sign lead optimization agreement for cancer

REP-9: A highly potent broad-spectrum antiviral agent

Selective dual-specificity phosphatase inhibitors with potential as anticancer agents

Novel mechanism of antitumor activity demonstrated for NK-314

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...